| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 203 companies in the Health Care Equipment & Supplies industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 8, 2024 | RGEN Repligen Corp | Hunt Anthony75 | Chief Executive Officer | Sell | 16,707 | $197.44 | $3,298,632.04 | -1.1% | -24.0% | -20.3% | |
| Mar 8, 2024 | TMDX Transmedics Group, Inc. | Khayal Tamer I53 | Chief Commercial Officer | Sell | 1,417 | $87.80 | $124,412.71 | -2.7% | +58.8% | -19.5% | |
| Mar 8, 2024 | TMDX Transmedics Group, Inc. | Gordon Stephen52 | Chief Financial Officer | Sell | 1,903 | $87.63 | $166,759.89 | -7.6% | +58.8% | -19.5% | |
| Mar 8, 2024 | CERS Cerus Corp | Benjamin Richard J71 | Chief Medical Officer | Sell | 29,378 | $2.40 | $70,457.26 | -5.8% | -16.4% | -33.2% | |
| Mar 8, 2024 | LMAT Lemaitre Vascular Inc | Kamke Trent G53 | Senior V. P., Operations | Sell | 4,542 | $68.18 | $309,684.41 | -30.8% | +15.8% | +21.1% | |
| Mar 8, 2024 | COO Cooper Companies, Inc. | Weiss Robert S55 | Director | Sell | 241,288 | $102.20 | $24,659,342.12 | -29.9% | -6.2% | -16.3% | |
| Mar 8, 2024 | HOLX Hologic Inc | Dockendorff Charles J56 | Director | Sell | 1,465 | $76.21 | $111,647.65 | -48.2% | -2.9% | -16.2% | |
| Mar 8, 2024 | ICUI Icu Medical Inc/de | Sanzone Virginia Ruth64 | VP, General Counsel | Sell | 3,300 | $104.57 | $345,088.26 | -40.9% | +3.7% | +35.8% | |
| Mar 8, 2024 | HOLX Hologic Inc | Crawford Sally | Director | Sell | 9,039 | $76.40 | $690,606.72 | -6.4% | -2.9% | -16.2% | |
| Mar 8, 2024 | WRBY Warby Parker Inc. | Gilboa David Abraham62 | Co-chief Executive Officer | Sell | 80,376 | $12.09 | $971,527.68 | -76.6% | +39.9% | +73.7% | |
| Mar 8, 2024 | ICUI Icu Medical Inc/de | Lopez George A45 | Director | Sell | 41,377 | $106.00 | $4,386,154.57 | -3.9% | +3.7% | +35.8% | |
| Mar 7, 2024 | AXGN Axogen, Inc. | Freitag Gregory Gene68 | Director | Sell | 25,000 | $9.00 | $225,000.00 | -8.4% | -22.4% | +96.6% | |
| Mar 7, 2024 | AXGN Axogen, Inc. | Donovan Michael Patrick | VP Operations | Sell | 36,310 | $8.81 | $319,891.10 | -50.4% | -22.4% | +96.6% | |
| Mar 7, 2024 | LMAT Lemaitre Vascular Inc | Roush John A49 | Director | Sell | 7,500 | $69.00 | $517,500.00 | -76.7% | +17.2% | +18.5% | |
| Mar 7, 2024 | EW Edwards Lifesciences Corp | Lippis Daniel J.62 | Cvp, Japac | Sell | 1,715 | $90.98 | $156,030.70 | -9.1% | -7.2% | -25.0% | |
| Mar 7, 2024 | ATEC Alphatec Holdings, Inc. | Blackford Quentin S.60 | Director | Buy | 20,000 | $12.83 | $256,600.00 | +3.6% | -22.9% | -18.9% | |
| Mar 7, 2024 | SYK Stryker Corp | Berry William E Jr | VP, Chief Accounting Officer | Sell | 7,690 | $358.48 | $2,756,729.66 | -67.7% | -3.3% | +6.1% | |
| Mar 7, 2024 | MMSI Merit Medical Systems Inc | Wright Joseph47 | Chief Commercial Officer | Sell | 25,000 | $75.68 | $1,891,925.00 | -37.2% | +10.6% | +32.6% | |
| Mar 7, 2024 | ZBH Zimmer Biomet Holdings, Inc. | Yi Sang62 | Group President, Asia Pacific | Sell | 1,705 | $126.86 | $216,296.30 | -8.6% | -11.6% | -15.2% | |
| Mar 7, 2024 | GKOS Glaukos Corp | Kliman Gilbert H64 | Director | Sell | 13,347 | $86.43 | $1,153,557.31 | -27.1% | +29.0% | +17.2% | |
| Mar 7, 2024 | WRBY Warby Parker Inc. | Blumenthal Neil Harris66 | Co-chief Executive Officer | Sell | 78,311 | $12.21 | $956,334.68 | -76.3% | +38.9% | +69.8% | |
| Mar 7, 2024 | RVP Retractable Technologies Inc | Shaw Thomas J50 | President And CEO | Buy | 6,068 | $1.23 | $7,445.68 | - | -11.5% | -37.9% | |
| Mar 7, 2024 | ISRG Intuitive Surgical Inc | Brosius Mark56 | SVP &Chief Mfg And Supply Cha | Sell | 588 | $393.35 | $231,291.76 | -10.6% | +6.3% | +32.0% | |
| Mar 6, 2024 | IDXX Idexx Laboratories Inc /de | Polewaczyk James F66 | Executive Vice President | Sell | 8,104 | $558.44 | $4,525,596.16 | -18.1% | -11.9% | -23.0% | |
| Mar 6, 2024 | PACB Pacific Biosciences Of California, Inc. | Meline David W | Director | Buy | 40,000 | $4.40 | $176,160.00 | New | -56.9% | -68.9% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.